DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings
Gamida Cell, a leading cellular and immune therapeutics company, today announced two presentations from its NiCord programs in high-risk hematologic malignancies and sickle cell disease (SCD) at the 2018 BMT Tandem Meetings, held from February 21 – 25 at the Salt Palace Convention Center in Salt Lake City, UT.
Details for the presentations are as follows:
-NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial; Mitchell Horwitz, M.D., Session G: Alternative Donor / Immune Reconstitution, Feb. 23, 2018 at 10:30 a.m. MT in Ballroom I
-A Novel Therapy for Sickle Cell Disease (SCD): Co-Transplantation of NiCord [Ex-Vivo Expanded Umbilical Cord Blood (UCB) Progenitor Cells with Nicotinamide] and an Unmanipulated Unrelated UCB Graft Leads to Successful Engraftment and Cure of Severe SCD; Suhag H. Parikh, M.D., Poster Session 1: Cord Blood, Feb. 21, 2018 at 6:45 p.m. MT in Hall E
+myBinderRelated Content
-
education & research8 Tips to Support Students With Sickle Cell DiseaseIn the United States, sickle cell diseas...
-
news & eventsL-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
education & researchGum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trialBackground: Sickle cell anemia patien...
-
news & eventsADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
news & eventsSafety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
news & eventsDiscovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
-
news & eventsPartnership to Ensure Supply of LentiGlobin, Potential Gene TherapyBluebird Bio extended a partnership with...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.